Darunavir
- Generic Name
- Darunavir
- Brand Names
- Prezcobix, Prezista, Rezolsta, Darunavir Viatris (previously Darunavir Mylan), Darunavir Krka
- Drug Type
- Small Molecule
- Chemical Formula
- C27H37N3O7S
- CAS Number
- 206361-99-1
- Unique Ingredient Identifier
- YO603Y8113
- Background
Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy. It was initially approved by the FDA in 2006.
...
- Indication
Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Comparative Study of Three NNRTI-Sparing HAART Regimens
- Conditions
- Interventions
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2014-09-05
- Target Recruit Count
- 1814
- Registration Number
- NCT00811954
- Locations
- 🇺🇸
The Ponce de Leon Center CRS, Atlanta, Georgia, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Trinity Health and Wellness Center, Dallas, Texas, United States
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00783484
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
NNRTI/PI Toxicity Switch to Darunavir Study
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 12
- Registration Number
- NCT00765154
- Locations
- 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT00757783
TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet
- Conditions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2011-06-09
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 23
- Registration Number
- NCT00752310
TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2011-06-09
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 21
- Registration Number
- NCT00744887
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Dallas VA Medical Center
- Target Recruit Count
- 85
- Registration Number
- NCT00677300
- Locations
- 🇺🇸
Dallas VA Medical Center, Dallas, Texas, United States
🇺🇸Parkland Health & Hospital System, Dallas, Texas, United States
Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 32
- Registration Number
- NCT00630734
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Characterization of Acute and Recent HIV-1 Infections in Zurich.
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 800
- Registration Number
- NCT00537966
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 517
- Registration Number
- NCT00537394
- Locations
- 🇺🇸
Children's National Med. Ctr. ATN CRS, Washington, District of Columbia, United States
🇺🇸Univ. of Rochester ACTG CRS, Rochester, New York, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.